Editorial

新薬発売の失敗

Nature Biotechnology 31, 1 doi: 10.1038/nbt.2482

A slew of disappointing product launches suggests biotech companies are ill prepared to navigate an increasingly parsimonious reimbursement environment.

目次へ戻る

プライバシーマーク制度